Home News & Events Events Workshops Workshops Page tools Share Share Share on LinkedinShare on BlueskyShare on XShare on Facebook Print Search Email Accessibility Workshop NONMEM Introduction Workshop (China Region): Applications in PK/PD Modeling (Mandarin Language) Date 31 July 2026 Time 09:00 - 12:00 Location Online/Virtual Webex Timezone Asia/Shanghai Workshop NONMEM Introduction Workshop (China Region): Applications in PK/PD Modeling (Mandarin Language) Date 3 September 2026 Time 09:00 - 12:00 Location Online/Virtual Webex Timezone Asia/Shanghai Workshop Beginners/Intermediate Online NONMEM/PDx-Pop Workshop Date 22 September 2026 - 23 September 2026 Time 09:00 - 17:00 Location Online/Virtual Webex Timezone America/New York Workshop Advanced Online NONMEM/PDx-Pop Workshop Date 24 September 2026 Time 09:00 - 17:00 Location Online/Virtual Webex Timezone America/New York Workshop New and Advanced Features of NONMEM 7.6 at ACoP 2026 In Person Workshop Date 11 October 2026 Time 08:00 - 17:00 Location Gaylord National Resort & Convention Center, Oxon Hill, Maryland, USA. Timezone America/New York In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events ASCO 2026 ISPOR EU 2026 Webinars Workshops Webinars Social media hub Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related information: Event Webinars Event Industry Events What’s happening in ICON ICON Plc While recurrence free survival is the accepted surrogate endpoint for oncology, biomarker-based outcomes assessment with ctDNA may offer greater precision and sensitivity. What could acceptance of biomarker-based surroga... 7 Jul View post View webpage ICON Plc What would make you return to a former employer? After more than a decade building his career across pharma and CROs, Albert Bekfi returned to ICON as Vice President, Pharmacovigilance and Safety Reporting, Service Deli... 7 Jul View post View webpage ICON Plc Winning Best Clinical Trial Supplier: Site Innovation at ABEA 2026 is a testament to the outstanding collaboration, expertise and commitment of ICON’s APAC teams. We thank IMAPAC for recognising innovation that ultimate... 7 Jul View post View webpage ICON Plc Tissue‑based screening workflows create weeks‑long delays and site burden; shifting screening infrastructure toward blood‑based ctDNA assays may identify eligible patients within days while preserving analytic rigor. Exp... 6 Jul View post View webpage ICON Plc What will it take to translate ambition into measurable progress in clinical trial representation? Tinaya Gray, Executive Director of ICON Site Engagement & PACE, joined ACRO’s Good Clinical Podcast to discuss how the i... 6 Jul View post View webpage ICON Plc We’re excited to be part of #SCDMChina this year, taking place from 3 - 4 July in Shanghai. Visit booth \#6 tomorrow to meet our team and learn how ICON is revolutionising clinical research with cutting-edge data-driven ... 2 Jul View post View webpage ICON Plc Oligonucleotide (ON) drug development is accelerating rapidly—but first‑in‑human (FIH) studies remain complex. Listen to our recent webinar where specialists discussed: - Translational PK/PD and toxicity considerations ... 2 Jul View post View webpage ICON Plc The recent implementation of ICH Q5A(R2) marks the most consequential shift in viral safety for biotechnology products since the 1990s, moving sponsors toward risk based, technology enabled controls that can shorten test... 2 Jul View post View webpage ICON Plc Many molecularly guided treatments with tumor-agnostic potential are still modulated by lineage-specific biology. Emerging tools that predict whether a molecular target is appropriate for tumor-agnostic development could... 1 Jul View post View webpage ICON Plc Global trends for drug-device combination product regulation are moving toward an integrated approach, shifting away from quality systems that prioritise just one component of the combination. From integrated quality sy... 1 Jul View post View webpage ICON Plc How will the latest regulatory changes impact your biosimilar strategy? The March 2026 updates from the EMA and FDA are redefining expectations — from reduced reliance on comparative efficacy studies to more streamlined... 1 Jul View post View webpage ICON Plc The shift towards real-time clinical trials could reduce long-standing inefficiencies in data flow and accelerate early decision-making. However, greater transparency also introduces new challenges in governance, data ma... 1 Jul View post View webpage
